GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MEI Pharma Inc (NAS:MEIP) » Definitions » Change In Other Working Capital

MEI Pharma (MEI Pharma) Change In Other Working Capital : $-68.79 Mil (TTM As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is MEI Pharma Change In Other Working Capital?

MEI Pharma's Change In Other Working Capital for the quarter that ended in Dec. 2023 was $-0.35 Mil. It means MEI Pharma's Other Working Capital declined by $0.35 Mil from Sep. 2023 to Dec. 2023 .

MEI Pharma's Change In Other Working Capital for the fiscal year that ended in Jun. 2023 was $-31.84 Mil. It means MEI Pharma's Other Working Capital declined by $31.84 Mil from Jun. 2022 to Jun. 2023 .

MEI Pharma Change In Other Working Capital Historical Data

The historical data trend for MEI Pharma's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MEI Pharma Change In Other Working Capital Chart

MEI Pharma Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Change In Other Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.99 75.88 -3.91 15.38 -31.84

MEI Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Change In Other Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -27.34 -1.63 -1.59 -65.21 -0.35

MEI Pharma Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-68.79 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MEI Pharma Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of MEI Pharma's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

MEI Pharma (MEI Pharma) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MEI Pharma Inc (NAS:MEIP) » Definitions » Change In Other Working Capital
Comparable Companies
SNSE ONCT SLGL LSTA UBX LPCN BCLI AGE ABIO IGC OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX
Traded in Other Exchanges
N/A
Address
11455 El Camino Real, Suite 250, San Diego, CA, USA, 92130
Website
https://www.meipharma.com
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
Executives
Taheer Datoo director 181 BAY STREET, SUITE 4200, TORONTO A6 M5J 2T3
James P Flynn director 41 HARRIS CT, DANVILLE CA 94526
Sujay Kango director 1028 CHAMBERS COURT, BRIDGEWATER NJ 08807
Richard G Ghalie officer: Chief Medical Officer C/O FAVRILLE, INC, 10445 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Bruce Ross Winson 10 percent owner 5950 BERKSHIRE LANE, SUITE 510, DALLAS TX 75225
Anson Funds Management Lp 10 percent owner 16000 DALLAS PARKWAY, SUITE 800, DALLAS TX 75248
Anson Management Gp Llc 10 percent owner 16000 DALLAS PARKWAY, SUITE 800, DALLAS TX 75248
Anson Advisors Inc. 10 percent owner 155 UNIVERSITY AVENUE, SUITE 207, TORONTO A6 M5H 3B7
Funicular Funds, Lp 10 percent owner 2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Amin Nathoo 10 percent owner 155 UNIVERSITY AVENUE, SUITE 207, TORONTO Z4 M5H 3B7
Moez Kassam 10 percent owner 111 PETER STREET, SUITE 904, TORONTO A6 M5V2H1
Justin J. File officer: CFO and Corporate Secretary C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Jacob Ma-weaver 10 percent owner 2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Cable Car Capital Llc 10 percent owner 2261 MARKET STREET #4307, SAN FRANCISCO CA 94114
Baltic Charles V. Iii director C/O MARSHALL EDWARDS, INC., 11975 EL CAMINO REAL, SUITE 101, SAN DIEGO CA 92130